Merck posts Q2 earnings miss, unveils cost-cutting initiative

Merck & Co. (NYSE:MRK) shares fell 7% after reporting Q2 adjusted EPS of $2.13 and revenue of $15.8 billion, both missing analyst estimates, primarily due to a 55% drop in Gardasil sales driven by China market issues. Despite strong growth in its flagship cancer drug, the company narrowed its full-year 2025 guidance. In response, Merck announced a multiyear optimization initiative targeting $3 billion in annual savings by 2027, alongside ongoing strategic acquisitions, signaling a proactive approach to portfolio transformation and future value generation.

Analysis

Merck's Q2 2025 financial results disappointed investors, leading to a 7% share price decline. The company reported adjusted EPS of $2.13, falling short of analyst estimates, alongside revenue of $15.8 billion, which marked a 2% year-over-year decrease. The primary driver for the underperformance was a stark 55% collapse in Gardasil vaccine sales, a result of shipment suspensions and suppressed demand in China. This significant headwind masked the continued strength of its flagship cancer drug franchise, which posted 9% year-over-year growth to $8 billion, beating forecasts. In response to the challenging quarter, Merck narrowed its full-year 2025 guidance and announced a substantial multiyear optimization initiative designed to generate $3 billion in annual savings by 2027. This defensive cost-cutting, combined with strategic moves like the pending acquisition of Verona Pharma, indicates management is actively reallocating resources from mature product lines to new growth drivers to navigate current pressures and reshape its long-term portfolio.

Key Decisions for Investors

• Investors should scrutinize future earnings reports for any stabilization in Gardasil sales in China, as this remains the most significant near-term drag on revenue.
• Consider the execution risk and potential long-term margin benefits of the newly announced $3 billion cost-optimization program, as its success is now pivotal to offsetting top-line weakness.
• Re-evaluate valuation models following the 7% stock decline to determine if the market has fully priced in the near-term headwinds from Gardasil and the narrowed guidance, while still accounting for the robust growth in the oncology segment.